Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARKLE: Mangoral for liver MRI in renal impairment
NCT04119843Phase 3Completed
- Sponsor
- Ascelia Pharma AB
- Start
- Feb 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of Mangoral in focal liver lesion, sponsored by Ascelia Pharma AB. Primary endpoints: Lesion Border Delineation in Combined MRI Compared to Unenhanced MRI and Lesion Contrast in Combined MRI Compared to Unenhanced MRI. Started Feb 2020; status: completed.
02
Drugs
Mangoral
03
Conditions
focal liver lesion
Beyond the preview
Go deeper on NCT04119843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04119843.